--- title: "Mazdutide | PepTracker Pro" description: "The first dual GCG/GLP-1 receptor agonist approved in China for obesity and T2D, with Phase 3 showing up to 20.1% weight loss at the 9 mg dose and superiority over semaglutide." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Mazdutide", "description": "The first dual GCG/GLP-1 receptor agonist approved in China for obesity and T2D, with Phase 3 showing up to 20.1% weight loss at the 9 mg dose and superiority over semaglutide.", "url": "https://peptrackerpro.com/peptides/mazdutide", "lastReviewed": "2026-05-02", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Mazdutide", "item": "https://peptrackerpro.com/peptides/mazdutide" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People following emerging metabolic drug pipelines?", "acceptedAnswer": { "@type": "Answer", "text": "Mazdutide is a research peptide studied in preclinical models. The first dual GCG/GLP-1 receptor agonist approved in China for obesity and T2D, with Phase 3 showing up to 20.1% weight loss at the 9 mg dose and superiority over semaglutide." } }, { "@type": "Question", "name": "Those comparing next-generation GLP-1 compounds?", "acceptedAnswer": { "@type": "Answer", "text": "Mazdutide is a research peptide studied in preclinical models. The first dual GCG/GLP-1 receptor agonist approved in China for obesity and T2D, with Phase 3 showing up to 20.1% weight loss at the 9 mg dose and superiority over semaglutide." } }, { "@type": "Question", "name": "Individuals researching dual agonist approaches?", "acceptedAnswer": { "@type": "Answer", "text": "Mazdutide is a research peptide studied in preclinical models. The first dual GCG/GLP-1 receptor agonist approved in China for obesity and T2D, with Phase 3 showing up to 20.1% weight loss at the 9 mg dose and superiority over semaglutide." } } ] } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Peptides](/peptides)/ Mazdutide **Research-only content.** This page is for educational purposes and does not constitute medical advice. [Read full disclaimer →](/research-disclaimer) # Mazdutide High Evidence The first dual GCG/GLP-1 receptor agonist approved in China for obesity and T2D, with Phase 3 showing up to 20.1% weight loss at the 9 mg dose and superiority over semaglutide. Aliases IBI362 +1 more Evidence High Evidence Last Updated 2026-05-02 Reading Time 2 min ## Table of Contents 1. [What It Is](#what-it-is) 2. [Regulatory Status](#regulatory-status) 3. [Proposed Mechanisms](#proposed-mechanisms) 4. [Evidence Snapshot](#evidence-snapshot) 5. [Commonly Discussed Benefits](#benefits) 6. [Safety & Cautions](#safety) 7. [Comparisons](#comparisons) 8. [Calculator Tools](#calculator) 9. [Citations](#citations) ## What It Is Mazdutide (IBI362/LY3305677) is a first-in-class dual glucagon (GCG)/GLP-1 receptor agonist developed by Innovent Biologics in partnership with Eli Lilly. China's NMPA approved mazdutide for chronic weight management in adults with overweight or obesity, making it the first dual GCG/GLP-1 agonist approved anywhere globally. A separate NMPA approval was granted for glycemic control in adults with type 2 diabetes. In the GLORY-1 Phase 3 trial, the 6 mg dose produced 14.01% mean body weight reduction at 48 weeks versus 0.30% with placebo. The GLORY-2 Phase 3 trial of the 9 mg dose achieved up to 20.1% weight loss at 60 weeks in Chinese adults with obesity, with the NDA submission for the 9 mg dose expected in 2026. In the head-to-head DREAMS-3 Phase 3 trial, mazdutide demonstrated superiority over semaglutide in both glycemic control and weight loss in Chinese adults with type 2 diabetes. The GLORY-3 trial is evaluating mazdutide versus semaglutide in adults with obesity and metabolic-associated fatty liver disease (MAFLD), and GLORY-OSA is evaluating mazdutide in obesity with obstructive sleep apnea. Seven Phase 3 studies have been completed or are ongoing. Global regulatory filings outside China are expected. Also known as: IBI362, LY3305677 ## Regulatory Status NMPA-Approved (China) Approved by China's NMPA for chronic weight management (6 mg) and glycemic control in T2D. 9 mg dose NDA pending. Not yet approved by FDA; global regulatory filings expected. Effective: 2025 [View FDA Source](https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-first-dual-gcgglp-1-receptor-agonist-received-approval-from-chinas-nmpa-for-chronic-weight-management-302493152.html) ## Proposed Mechanisms - GLP-1 receptor agonism reduces appetite and promotes satiety - Glucagon receptor activation increases energy expenditure and hepatic fat oxidation - Dual mechanism addresses both caloric intake and metabolic rate - Improves insulin sensitivity and glucose homeostasis in T2D - Reduces hepatic lipid accumulation through glucagon-mediated lipolysis ## Evidence Snapshot High Evidence Low Medium High Study Type Model Outcome Link Human (Phase 3) Chinese adults with obesity (NEJM) 14.01% weight loss at 48 weeks (6mg) vs 0.30% placebo [Source](https://www.nejm.org/doi/full/10.1056/NEJMoa2411528) Human (Phase 3) Chinese adults with T2D (Nature) HbA1c reduction of 2.15% (6mg) vs 0.14% placebo at 24 weeks [Source](https://www.nature.com/articles/s41586-025-10026-w) Human (Phase 3) Head-to-head vs dulaglutide in T2D (Nature) Superior glycemic control and weight loss vs dulaglutide [Source](https://www.nature.com/articles/s41586-025-10031-z) Human (Phase 3, GLORY-2) Mazdutide 9 mg in Chinese adults with obesity (60 weeks) Up to 20.1% weight loss at 60 weeks; met all primary and key secondary endpoints [Source](https://www.prnewswire.com/news-releases/mazdutide-9-mg-achieves-up-to-20-1-weight-loss-in-chinese-adults-with-obesity-glory-2-study-meets-primary-and-all-key-secondary-endpoints-302620471.html) Human (Phase 3, DREAMS-3) Head-to-head vs semaglutide in Chinese adults with T2D Superiority over semaglutide in both glycemic control and weight loss [Source](https://www.prnewswire.com/news-releases/innovents-mazdutide-shows-superiority-in-glycemic-control-with-weight-loss-over-semaglutide-in-a-head-to-head-phase-3-clinical-trial-dreams-3-302594633.html) Human (Phase 1) High-dose (up to 10mg) in adults with overweight/obesity Significant dose-dependent weight reduction [Source](https://pmc.ncbi.nlm.nih.gov/articles/PMC12515780/) ## Commonly Discussed Benefits [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism) Researching Mazdutide ? Track it, set reminders, and keep notes in the free app. [Track in App](https://app.peptrackerpro.com/?add=mazdutide) ## Safety & Cautions - Approved in China only; not yet approved by FDA or EMA - Phase 3 data primarily in Chinese populations; global trials needed - Gastrointestinal side effects are the most common adverse events - Long-term cardiovascular outcome data not yet available - 9 mg high-dose NDA under review by NMPA ## Comparisons See how Mazdutide compares to related peptides: [Mazdutide vs Efinopegdutide](/compare/mazdutide-vs-efinopegdutide) [Mazdutide vs Efocipegtrutide](/compare/mazdutide-vs-efocipegtrutide) [Mazdutide vs Efpeglenatide](/compare/mazdutide-vs-efpeglenatide) [Mazdutide vs NA-931 (Bioglutide)](/compare/mazdutide-vs-na-931) [Mazdutide vs Pegozafermin](/compare/mazdutide-vs-pegozafermin) [Mazdutide vs Retatrutide](/compare/mazdutide-vs-retatrutide) [Mazdutide vs Semaglutide](/compare/mazdutide-vs-semaglutide) [Mazdutide vs Survodutide](/compare/mazdutide-vs-survodutide) [Mazdutide vs Tirzepatide](/compare/mazdutide-vs-tirzepatide) [Mazdutide vs UBT251](/compare/mazdutide-vs-ubt251) ## Calculator Tools Use our research tools to explore dosing and reconstitution data: [Reconstitution Calculator](/calculators) ## Citations 1. \[1\] Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight, NEJM 2025 [PubMed](https://www.nejm.org/doi/full/10.1056/NEJMoa2411528) 2. \[2\] Mazdutide versus placebo in Chinese adults with T2D, Nature 2025 [PubMed](https://www.nature.com/articles/s41586-025-10026-w) 3. \[3\] Mazdutide versus dulaglutide in Chinese adults with T2D, Nature 2025 [PubMed](https://www.nature.com/articles/s41586-025-10031-z) 4. \[4\] GLORY-2: Mazdutide 9 mg achieves up to 20.1% weight loss — PRNewswire 2026 [PubMed](https://www.prnewswire.com/news-releases/mazdutide-9-mg-achieves-up-to-20-1-weight-loss-in-chinese-adults-with-obesity-glory-2-study-meets-primary-and-all-key-secondary-endpoints-302620471.html) 5. \[5\] DREAMS-3: Mazdutide shows superiority over semaglutide — Innovent 2026 [PubMed](https://www.prnewswire.com/news-releases/innovents-mazdutide-shows-superiority-in-glycemic-control-with-weight-loss-over-semaglutide-in-a-head-to-head-phase-3-clinical-trial-dreams-3-302594633.html) 6. \[6\] Innovent announces NMPA approval for T2D — PRNewswire 2026 [PubMed](https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-received-approval-from-chinas-nmpa-for-glycemic-control-in-adults-with-type-2-diabetes-302561434.html) ### Keep researching in the app - Log Mazdutide to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack [Open PepTracker Pro Free](https://app.peptrackerpro.com/?add=mazdutide) [Browse more peptides](/peptides) ## Related Peptides ### Efinopegdutide Medium Evidence Efinopegdutide (MK-6024, formerly HM12525A and JNJ-64565111) is an investigational once-weekly subcutaneous dual agonist of the GLP-1 and glucagon receptors being developed by Merck for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and steatotic liver disease. It is a synthetic oxyntomodulin-based peptide - a modified GLP-1/glucagon dual-agonist sequence conjugated to a human IgG4 Fc fragment through a 10 kDa polyethylene glycol linker using Hanmi Pharmaceutical's LAPSCovery half-life-extension platform, which stretches dosing to once weekly. The design pairs the GLP-1 arm (appetite suppression, glycemic control, weight loss) with a glucagon arm that raises energy expenditure and acts directly on the liver to burn hepatic fat - the feature that sets it apart from pure GLP-1 drugs. In the head-to-head Phase 2a trial in NAFLD (Journal of Hepatology, 2023), efinopegdutide 10 mg cut liver fat content by 72.7% at 24 weeks versus 42.3% for semaglutide 1 mg, with two-thirds of efinopegdutide recipients falling below the 5% liver-fat threshold that defines a normal liver. Merck holds FDA Fast Track designation for the MASH program and is running Phase 2b studies plus a dedicated trial in compensated cirrhosis due to steatohepatitis; the earlier type 2 diabetes and obesity indications were discontinued in favor of the liver focus. [metabolic-health](/benefits/metabolic-health)[Liver Health](/benefits/liver-health)[Weight Management](/benefits/weight-management)[disease-modification](/benefits/disease-modification)+1 more [View Details](/peptides/efinopegdutide) [\+ Compare](/compare?select=efinopegdutide)[](https://app.peptrackerpro.com/?add=efinopegdutide) ### Efocipegtrutide Medium Evidence Efocipegtrutide (Hanmi code HM15211) is an investigational, long-acting, once-weekly GLP-1/GIP/glucagon 'triple' receptor agonist being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) rather than obesity alone. It is built on Hanmi's LAPSCovery platform as a chemical conjugate of a chimeric tri-agonist peptide (TA15211) fused to a human IgG4 Fc fragment, which extends its half-life via FcRn-mediated recycling and enables weekly subcutaneous dosing. By adding glucagon-receptor activation to the GLP-1/GIP dual mechanism, efocipegtrutide is designed to combine appetite suppression and glycemic control with increased energy expenditure and direct hepatic anti-steatotic, anti-inflammatory, and anti-fibrotic effects. In a Phase 1b/2a study in obese subjects with non-alcoholic fatty liver disease, 12 weeks of treatment reduced liver fat by roughly 20% to 59% (dose-dependent, MRI-PDFF) versus about 6% on placebo. It has FDA Fast Track designation for MASH and orphan-drug designations from the FDA and EMA for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and idiopathic pulmonary fibrosis (IPF). The 52-week adaptive Phase 2 HM-TRIA-201 study (NCT04505436) in biopsy-confirmed MASH with fibrosis is the pivotal read the field is watching. [Liver Health](/benefits/liver-health)[Weight Management](/benefits/weight-management)[Glycemic Control](/benefits/glycemic-control)[Metabolism](/benefits/metabolism) [View Details](/peptides/efocipegtrutide) [\+ Compare](/compare?select=efocipegtrutide)[](https://app.peptrackerpro.com/?add=efocipegtrutide) ### Efpeglenatide Low Evidence A once-weekly, long-acting GLP-1 receptor agonist from Hanmi Pharmaceutical built on a different molecular backbone than semaglutide or liraglutide: instead of a modified human GLP-1, efpeglenatide uses exendin-4 - the naturally DPP-4-resistant GLP-1 mimic first found in Gila monster venom - fused to a fragment of a human antibody (an IgG4 Fc) through a small polyethylene-glycol (mini-PEG) linker using Hanmi's LAPSCOVERY half-life-extension platform. That design lets one subcutaneous injection lower blood sugar, curb appetite and reduce body weight for a full week. Efpeglenatide is best known for the landmark AMPLITUDE-O cardiovascular outcomes trial (NEJM 2021), in which 4,076 people with type 2 diabetes and cardiovascular or kidney disease had a 27% lower rate of major adverse cardiovascular events (MACE hazard ratio 0.73) and a 32% lower rate of a composite kidney outcome (hazard ratio 0.68) versus placebo - the first cardiovascular outcomes win for an exendin-based GLP-1 and one of the clearest kidney signals in the class, with benefit seen regardless of whether patients were also taking an SGLT2 inhibitor. Originally licensed to Sanofi and then returned to Hanmi in 2020, efpeglenatide is now being advanced primarily for obesity and overweight, with a Phase 3 program that has completed enrollment and a targeted first launch in South Korea in the second half of 2026. It is an investigational (not yet approved) prescription medicine, not a supplement or research chemical. [weight-loss](/benefits/weight-loss)[blood-sugar](/benefits/blood-sugar)[Cardiovascular](/benefits/cardiovascular)[kidney](/benefits/kidney) [View Details](/peptides/efpeglenatide) [\+ Compare](/compare?select=efpeglenatide)[](https://app.peptrackerpro.com/?add=efpeglenatide) ### NA-931 (Bioglutide) Medium Evidence The first oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors for obesity treatment with muscle preservation. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[muscle-preservation](/benefits/muscle-preservation)[Metabolism](/benefits/metabolism)+1 more [View Details](/peptides/na-931) [\+ Compare](/compare?select=na-931)[](https://app.peptrackerpro.com/?add=na-931) ### Pegozafermin Low Evidence Pegozafermin (development code BIO89-100) is an investigational, long-acting analog of fibroblast growth factor 21 (FGF21) being developed for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and for severe hypertriglyceridemia (SHTG). Originally developed by 89bio and acquired by Roche in a deal announced in September 2025 (about $2.4 billion upfront and up to roughly $3.5 billion including a contingent value right), it uses site-specific glycoPEGylation to extend the very short half-life of native FGF21 to roughly 55-100 hours, enabling once-weekly or once-every-two-weeks subcutaneous dosing. FGF21 is a metabolic hormone that acts on liver, fat, and other tissues to improve insulin sensitivity, lower triglycerides, and exert direct anti-fibrotic and anti-inflammatory effects. In the Phase 2b ENLIVEN trial in biopsy-confirmed F2-F3 MASH, the 44 mg every-two-weeks dose produced at least a one-stage fibrosis improvement without worsening of MASH in about 27% of patients versus 7% on placebo, and MASH resolution without worsening of fibrosis in about 26% versus 2% on placebo, with benefits sustained through week 48. Pegozafermin holds FDA Breakthrough Therapy designation and EMA PRIME status for MASH and has advanced into the Phase 3 ENLIGHTEN program (ENLIGHTEN-Fibrosis in non-cirrhotic F2-F3 MASH and ENLIGHTEN-Cirrhosis in compensated F4 cirrhosis), plus the Phase 3 ENTRUST trial in SHTG. [metabolic dysfunction-associated steatohepatitis (MASH/NASH) - fibrosis improvement, MASH resolution, and reduced liver fat (investigational)]()[severe hypertriglyceridemia (SHTG) - large reductions in blood triglycerides (investigational; Phase 3 ENTRUST)]()[improved insulin sensitivity and glycemic markers]()[improvements in non-invasive markers of liver injury and fibrosis (liver fat by MRI-PDFF, liver enzymes, fibrosis biomarkers)]()+1 more [View Details](/peptides/pegozafermin) [\+ Compare](/compare?select=pegozafermin)[](https://app.peptrackerpro.com/?add=pegozafermin) ### Retatrutide High Evidence An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/retatrutide) [\+ Compare](/compare?select=retatrutide)[](https://app.peptrackerpro.com/?add=retatrutide) ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+3 more [View Details](/peptides/semaglutide) [\+ Compare](/compare?select=semaglutide)[](https://app.peptrackerpro.com/?add=semaglutide) ### Survodutide Medium Evidence A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/survodutide) [\+ Compare](/compare?select=survodutide)[](https://app.peptrackerpro.com/?add=survodutide) ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+1 more [View Details](/peptides/tirzepatide) [\+ Compare](/compare?select=tirzepatide)[](https://app.peptrackerpro.com/?add=tirzepatide) ### UBT251 Medium Evidence A GLP-1/GIP/glucagon triple receptor agonist in Phase 2 development for type 2 diabetes and obesity, competing with retatrutide in the triple-agonist space. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism)[Appetite Regulation](/benefits/appetite-regulation) [View Details](/peptides/ubt251) [\+ Compare](/compare?select=ubt251)[](https://app.peptrackerpro.com/?add=ubt251) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.